Navigating the Neurophysiology of Sleep and Cataplexy: The Significance of Select NeurotransmittersPremiere Date: Monday, May 9, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, May 9, 2023
Note: Credit Is No Longer Available
|Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology
|Phyllis C. Zee, MD, PhD
Professor of Neurology
Northwestern University Feinberg School of Medicine
Director, Sleep Disorders Center
Northwestern Memorial Hospital
Sleep is a complex physiological process that is mediated by a number of neurotransmitters — including histamine, acetylcholine, dopamine, gamma-amino butyric acid (GABA), norepinephrine, serotonin, glutamate, histamine, and orexin (or hypocretin). The interaction of these various neurotransmitters play different roles in the sleep-wake cycle to promote sleep and/or wakefulness in patients with narcolepsy. It is imperative that clinicians differentiate the neurotransmitters involved in the sleep-wake cycle and, when making treatment selections, apply knowledge of how novel therapies target those neurotransmitters to exert their clinical effect.
Join Drs. Thorpy and Zee in part two of a CMEOCast series on excessive daytime sleepiness (EDS) in narcolepsy as they walk clinicians through identifying the mechanisms of action (MOAs) of novel therapies and differentiating the neurotransmitters involved when individualizing therapy selection for optimal outcomes.
At the end of this CE activity, participants should be able to:
- Differentiate the neurotransmitters involved in cataplexy and the sleep-wake cycle, including their differential impact on wakefulness.
Supported by an educational grant from Harmony Biosciences, LLC.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry and/or primary care
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Thorpy reports the following financial relationships:
Advisory Board/Consultant: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma
Dr. Zee reports the following financial relationships:
Consultant: Eisai Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; Sanofi-Aventis; and Takeda Pharmaceutical Company Limited
Grants: Vanda Pharmaceuticals (Paid to Northwestern University)
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).